ArticleFrontiers in pharmacology2021
Piperlongumine Is an NLRP3 Inhibitor With Anti-inflammatory Activity.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Natural Products as NLRP3 Inflammasome Inhibitors: A Review.Molecules (Basel, Switzerland) · 2026Review
- Deciphering the NEK7-NLRP3 inflammasome assembly: from conformational activation to allosteric drug discovery.Frontiers in immunology · 2026Review
- From Ancient Spice to Advanced Science: Therapeutic, Nutraceutical and Nanotechnological Insights into the Fruits ofDrug design, development and therapy · 2026Review
- Monocyte/macrophage-derived NLRP3 Promotes the Onset and Progression of Ankylosing Spondylitis Via the NOD-like Receptor Pathway.Journal of clinical immunology · 2025Article
- Innovative green niosomal piperlongumine as a novel topical treatment for dermatophytosis in guinea pigs model.Scientific reports · 2025Article
- Synthesis, anticancer evaluation, preliminary mechanism study of novel 1, 2, 3-triazole-piperlongumine derivatives.Molecular diversity · 2025Article
- Integrated Phytochemical Profiling, UPLC-HRMS Characterization, and Bioactivity Evaluation ofInternational journal of molecular sciences · 2025Article
- Article
- NLRP3 inflammasome in health and disease (Review).International journal of molecular medicine · 2025Review
- Anti-inflammatory potential of Piper betleoides C. DC., a promising Piper species of Northeast India: in vitro and in vivo evidence and mechanistic insight.Inflammopharmacology · 2024Article
- Anti-inflammatory effect ofHeliyon · 2024Article
- Therapeutic Efficacy of Medicinal Plants with Allopathic Medicine in Musculoskeletal Diseases.International journal of plant, animal and environmental sciences · 2024Article
- Targeting NLRP3 Inflammasome: Structure, Function, and Inhibitors.Current medicinal chemistry · 2024Article
- Cuproptosis-related genes signature and validation of differential expression and the potential targeting drugs in temporal lobe epilepsy.Frontiers in pharmacology · 2023Article
- NEK7: a new target for the treatment of multiple tumors and chronic inflammatory diseases.Inflammopharmacology · 2022Review
- Activation and Pharmacological Regulation of Inflammasomes.Biomolecules · 2022Review
- The role of NLRP3 inflammasome in inflammation-related skeletal muscle atrophy.Frontiers in immunology · 2022Review
- The role of NLRP3 inflammasome in digestive system malignancy.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Piperlongumine (PL) is an alkaloid from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.